The recently introduced CRISPR/Cas technology has induced an unprecedented biological revolution. As such, there is an increasing demand on gene editing technologies, including single to multiple gene knockouts, transcriptional activation/repression, targeted single nucleotide modification or the precise replacement of genetic loci for the purpose of tagging or modification.
To meet the increasing demand, the IBC2 is building up the Frankfurt CRISPR/Cas Screening Platform (FCSP), led by Dr. Manuel Kaulich. On the basis of collaboration, the platform already supports both internal and external researchers with expertise, reagents and strategic advice on gene editing. Manuel guides researches along their individual needs, ranging from single to multiple gene editing events, specific gene replacements, to the generation of custom made gRNA libraries.
A recently published example is the work carried out together with the groups of Ivan Dikic, Simone Fulda and Mike Heilemann, who discovered that the linear ubiquitin coat surrounding intracellular Salmonella serves as a signaling hub to locally activate NF-κB and thereby restrict bacterial proliferation (van Wijk et al., Nature Microbiology, 2017). Within this project, they also described the deubiquitinating enzyme OTULIN as central regulator of M1-linked ubiquitin chains on bacterial coats. The FCSP generated OTULIN KO cells for the functional validation of this finding. This prominent example underlines the importance of employing cutting-edge technologies on leading scientific questions and highlights the collaborative nature pursued with the FCSP at the IBC2.
Any requests for collaboration can be addressed to Dr. Manuel Kaulich (Email; 069/6301-5450)